LCM
ACAD icon

Legato Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Legato Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,407
Closed -$225K – 729
2025
Q4 		$225K Buy
+8,407
New +$201K 0.02% 705
2024
Q1 		– Sell
-6,577
Closed -$206K – 564
2023
Q4 		$206K Buy
+6,577
New +$157K 0.03% 526
2018
Q1 		– Sell
-29,432
Closed -$886K – 124
2017
Q4 		$886K Sell
29,432
-4,316
-13% -$138K 0.13% 155
2017
Q3 		$1.27M Buy
33,748
+25,748
+322% +$838K 0.19% 133
2017
Q2 		$223K Buy
+8,000
New +$238K 0.1% 187

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Legato Capital Management's ACAD Position: Q1 2026 in Review

Legato Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 8,407 shares — an estimated $225K sold.

Legato Capital Management first reported a position in ACAD in Q2 2017 and held it in 5 quarters. The position peaked at $1.27M in Q3 2017. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Legato Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Legato Capital Management sold 8,407 Acadia Pharmaceuticals shares in Q1 2026, an estimated $225K.
  • Legato Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 5 quarters.
  • Legato Capital Management's Acadia Pharmaceuticals position peaked at $1.27M in Q3 2017.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.